NCT04113187View on ClinicalTrials.gov

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

May 19, 2022

Study Completion Date

May 19, 2022

Conditions
Hereditary Hemorrhagic TelangiectasiaOsler Weber Rendu Disease
Interventions
DRUG

Propranolol treatment

40 mg twice a day (morning and evening), per os, during three months

DRUG

Placebo

per os, twice a day (morning and evening) during three months

Trial Locations (1)

Unknown

CHU de Bordeaux - service de médecine interne, Bordeaux

All Listed Sponsors
collaborator

AMRO-HHT-France - Association Maladie de Rendu-Osler

UNKNOWN

lead

University Hospital, Bordeaux

OTHER

NCT04113187 - Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Biotech Hunter | Biotech Hunter